June 4, 2004
Triangle Business Journal
Biogen Idec and Irish partner Elan Corp. have submitted a marketing authorization application to the European Medicines Agency for approval of their multiple sclerosis treatment Antegren.
The drug, which could reach the U.S. market by mid-2005, is being developed as a follow-up to Biogen Idec's top selling drug, Avonex, a multiple sclerosis drug produced at the company's Research Triangle Park facilities.
About 1 million people worldwide suffer from MS, which is a chronic nervous system disease.
Cambridge, Mass.-based Biogen Idec has more than 450 employees at its
Research Triangle Park facilities.
Copyright © 2004, American City Business Journals Inc.